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A B S T R A C T
Atrophy of the brain grey matter (GM) is an accepted and important feature of multiple sclerosis (MS). However,
its accurate measurement is hampered by various technical, pathological and physiological factors. As a con-
sequence, it is challenging to investigate the role of GM atrophy in the disease process as well as the eﬀect of
treatments that aim to reduce neurodegeneration. In this paper we discuss the most important challenges cur-
rently hampering the measurement and interpretation of GM atrophy in MS. The focus is on measurements that
are obtained in individual patients rather than on group analysis methods, because of their importance in clinical
trials and ultimately in clinical care. We discuss the sources and possible solutions of the current challenges, and
provide recommendations to achieve reliable measurement and interpretation of brain GM atrophy in MS.
1. Introduction
Multiple sclerosis (MS) is a disease of the central nervous system
(CNS) that typically aﬀects both the brain and the spinal cord
(Compston and Coles, 2008). In addition to the well-known focal in-
ﬂammatory, demyelinating lesions that are typically seen in the white
matter (WM), MS also causes degeneration and consequent volume loss
of grey matter (GM), which is often referred to as GM atrophy. The
focus of the present paper will be on measurement of GM atrophy in the
brain, which is currently widely accessible as opposed to spinal cord
GM atrophy measurement. Nevertheless, GM atrophy in the spinal cord
is an important topic, accurate measurement of which can contribute to
better understanding MS and quantitatively characterizing its eﬀects in
individual patients in trials or clinical care. However, technical
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improvements are needed to obtain high resolution images at reduced
scan times and to increase coverage of the spinal cord, before broader
application is feasible (Kearney et al., 2015).
Brain GM atrophy is typically measured in vivo from standard 3D
T1-weighted images acquired by magnetic resonance imaging (MRI),
using automated analysis methods. Studies have demonstrated volume
decrease of subcortical GM structures and volume or thickness decrease
of cortical regions (Bergsland et al., 2012; Pareto et al., 2016). GM
atrophy in the brain has been shown to be associated with cognitive
impairment in MS (Nocentini et al., 2014; Riccitelli et al., 2011). Fur-
thermore, atrophy of the deep GM (DGM) structures, such as thalamus,
has been shown to be strongly related to clinical and cognitive decline
(Bermel et al., 2003; Houtchens et al., 2007; Pagani et al., 2005).
This paper, after reviewing the measurement techniques, will dis-
cuss the most important challenges for reliable measurement and in-
terpretation of brain GM atrophy in patients with MS. We divide these
challenges into two categories. Challenges in the category “Pathology,
physiology and treatment eﬀects” are: 1) Unclear pathological sub-
strate, 2) Evolution of GM atrophy, 3) Inﬂuence of physiological
variability, and 4) Evaluation of treatment response. “Measurement
challenges”, the second category, includes: 1) Inﬂuence of WM lesions,
2) Inﬂuence of atrophy itself, 3) Inﬂuence of other pathology, and 4)
Technical variability. For each section, we provide speciﬁc re-
commendations (summarized in Box 1) to improve measurement and
interpretation of GM atrophy in individual MS patients.
2. Review of measurement techniques
Various methods have been developed to measure anatomical
changes of the brain. Some of these techniques produce single-subject
measurements while others, such as voxel-based morphometry and
vertexwise analyses, provide group-based statistical tests. In the current
paper we are predominantly interested in the application of brain GM
atrophy measures in individual MS patients, because single-subject
measures are the most relevant outcome measures in clinical care and
clinical treatment trials. Therefore, this review discusses cortical and
deep GM atrophy measurement techniques with an emphasis on
methods that produce single-subject results, while brieﬂy reviewing
relevant aspects of methods for group-level analysis used in the litera-
ture.
2.1. Cortical atrophy measurement techniques
There is convincing evidence that MS involves structural cortical
changes resulting in atrophy (Charil et al., 2007; Lansley et al., 2013;
Narayana et al., 2012; Prinster et al., 2006; Ramasamy et al., 2009;
Sailer et al., 2003). Current MRI technology provides a valuable tool for
detecting and monitoring cortical atrophy early in the disease (Chard
et al., 2002; Chard et al., 2004; Dalton et al., 2004; De et al., 2003;
Sastre-Garriga et al., 2004; Sepulcre et al., 2006). For reproducible and
accurate estimation of cortical thickness (CTh), a number of automated
methods have been developed, such as FreeSurfer (Dale et al., 1999;
Fischl and Dale, 2000) (http://surfer.nmr.mgh.harvard.edu/fswiki/),
CIVET (Zijdenbos et al., 2002), and CLADA (Cortical Longitudinal
Atrophy Detection Algorithm) (Nakamura et al., 2011). For measure-
ment of cortical volume, other methods can be used such as SIENAX
(Smith et al., 2002) (cross-sectional pipeline of SIENA; Structural Image
Evaluation using Normalization of Atrophy), SIENAX multi-time-point
(SIENAX-MTP) (Dwyer et al., 2014), and SPM (Statistical Parametric
Mapping software) (Ashburner and Friston, 2005) or IBASPM (In-
dividual Brain Atlas using SPM) (Alemán-Gómez et al., 2006).
Automated methods for measuring CTh in MRI may be categorized
as surface-based, voxel-based, or a combination of the two categories
(Hutton et al., 2008). Currently, the majority of published studies that
employ automated methods for measuring CTh have been using sur-
face-based techniques for which the reliability has been investigated
(Han et al., 2006; Lerch and Evans, 2005). With these methods, the
thickness is calculated at each point on the extracted cortical surface
and surface-based smoothing is applied to the results. The beneﬁt of this
type of smoothing is that it prevents the problem of averaging across
diﬀerent banks of sulci and gyri (Hutton et al., 2009). However, this is
only the case if the surface has been accurately extracted. In general,
these methods are limited by the diﬃculty in obtaining homogeneous
GM boundaries due to the variation of contrast within the image that
results from MRI (B1) ﬁeld inhomogeneity. This problem has been
partly solved by using 3D T1-weighted images and by implementing
tools for intensity non-uniformity correction.
FreeSurfer (Dale et al., 1999; Fischl and Dale, 2000; Fischl et al.,
2002) calculates the CTh after inﬂation of the folded cortical surface
using tools for the analysis and visualization of structural MRI data
(Dale et al., 1999; Fischl and Dale, 2000). It contains a fully automated
structural imaging stream, although visual inspection and manual
editing (if necessary) are recommended at several stages in the pipeline.
For analysis of changes over time, FreeSurfer has a longitudinal pipeline
(Reuter et al., 2012).
CIVET (Zijdenbos et al., 2002) is a series of algorithms for cortico-
metric analysis of MR images including the extraction and analysis of
cortical surfaces from MR images, and other volumetric and cortico-
metric functions (Zijdenbos et al., 2002). In contrast to other software
such as FreeSurfer, CIVET is a fully automated method, which can be an
advantage for the analysis of large MR data sets.
CLADA (Zijdenbos et al., 2002) measures changes in CTh using
explicit deformable models. Like Freesurfer, CLADA allows the con-
current analysis of multiple time points, thereby improving quantiﬁ-
cation of within-patient change. The algorithm creates a deformable
model of the cerebral cortex consisting of two explicit surfaces based on
a combined image representing all time points, and then deforms the
model for each individual time point (Nakamura et al., 2011). An ad-
vantage of CLADA compared to other methods is that it can be applied
to 2D images with large slice thickness (3–5mm), which can be ad-
vantageous for retrospective analysis of clinical or trial data.
Voxel-based cortical thickness (VBCT) measurements do not require
the construction of a three-dimensional surface model (Han et al., 2006;
Hutton et al., 2009). This approach is a complementary technique to the
voxel-based morphometry (VBM) (Ashburner and Friston, 2000; Good
et al., 2001), which uses a mass-univariate approach with voxel-wise
comparisons of the local volume of GM across brain regions between
two groups of subjects. VBCT maps may be particularly advantageous
for the analysis of conditions that are associated with cortical thinning,
because the local topography of the GM is used to assign an absolute
metric to GM voxels (Hutton et al., 2009). In contrast, in VBM the local
GM volume is confounded by the convolution of the brain in a given
region. However, using both VBM and VBCT together might be a useful
tool for understanding the topography and time-course of cortical
atrophy in MS (Hutton et al., 2009).
Other methods such as SIENAX (Smith et al., 2002) (part of FSL,
http://fsl.fmrib.ox.ac.uk/fsl/fslwiki) and (IBA)SPM (Alemán-Gómez
et al., 2006; Ashburner and Friston, 2005) primarily use intensity his-
togram based voxelwise GM partial volume estimation. These have
been combined with anatomical atlases to separately quantify the total
volume of GM in cortical regions (Dupuy et al., 2016; Horakova et al.,
2008). SIENAX is the cross-sectional pipeline of the SIENA method
(Smith et al., 2002). Based on voxel intensities it estimates partial vo-
lume fractions of GM, WM and cerebrospinal ﬂuid (CSF) for each voxel.
The longitudinal SIENA only quantiﬁes overall brain volume change
(based on the shift of the parenchyma-CSF border over time), and
therefore does not measure GM or WM volume change separately. Two
diﬀerent extensions of SIENAX to perform direct longitudinal analysis
of GM or WM atrophy have recently been developed, both of which
combine cross-sectional and longitudinal modelling: SIENAX-MTP
(Dwyer et al., 2014) and SIENA-XL (Battaglini et al., 2016).
SPM (http://www.ﬁl.ion.ucl.ac.uk/spm/software/; (Penny et al.,
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2006)) is a MATLAB toolbox that performs segmentation providing
probability maps for GM, WM, and CSF. Individual Brain Atlas using
SPM (IBASPM, http://www.thomaskoenig.ch/Lester/ibaspm.htm) is an
SPM extension that uses the SPM segmentation and then warps a
standardized atlas to the individual scan to classify the image into
diﬀerent anatomical structures, in this case the cortical GM (Alemán-
Gómez et al., 2006). The GM volume of each structure is then quanti-
ﬁed. Both non-linear registration and GM segmentation processes are
performed using SPM subroutines; SPM12 includes symmetric regis-
tration procedures (Ashburner and Ridgway, 2012).
Longitudinal GM or WM volume changes can also be quantiﬁed
using Jacobian integration (Ashburner et al., 1998; Nakamura et al.,
2014). This is done by quantifying the total net amount of contraction
or expansion of a selected region in an image during an accurate non-
linear registration between the images of the ﬁrst and last time points.
Jacobian integration applied to longitudinal GM atrophy analysis has
shown to reduce variability related to measurement error compared to
other commonly used methods, thus potentially requiring smaller
sample sizes (Nakamura et al., 2014).
2.2. Deep GM atrophy measurement techniques
DGM atrophy has been shown to be associated with the develop-
ment of deﬁnite MS and disability progression in early relapsing re-
mitting MS (RRMS) (Mesaros et al., 2011; Rocca et al., 2010; Sepulcre
et al., 2006; Zivadinov et al., 2013a; Zivadinov et al., 2013b). However,
measurement of DGM atrophy remains challenging. To date, several
available tools have been developed for segmenting DGM structures,
some of which have been widely used in MS research. These methods
are based on combinations of various approaches and techniques such
as shape analysis (FIRST, FMRIB's Integrated Registration and Seg-
mentation Tool (Patenaude et al., 2011) and TOADS, Topology-pre-
serving Anatomy-Driven Segmentation, https://www.nitrc.org/
projects/toads-cruise/), voxelwise classiﬁcation (FreeSurfer, TOADS),
voxelwise partial volume estimation (SPM/IBASPM), topological con-
straints (TOADS) and brain atlases (IBASPM, FreeSurfer, TOADS). Here
we describe the principles of each method.
FIRST (part of the FSL toolbox) is a fully automated model-based
segmentation software (Patenaude et al., 2011). The model was trained
for 15 diﬀerent structures using 336 manually-labelled T1-weighted MR
images. FIRST models the outer surface of each DGM structure as a
mesh using models derived from the reference images and the local
intensity proﬁles around the mesh. Finally, while taking into account
the presence of neighboring structures, it labels voxels to assign them to
diﬀerent DGM structures.
FreeSurfer (Dale et al., 1999; Fischl et al., 1999) includes volumetric
segmentation of DGM structures. The processing brieﬂy includes re-
gistration to the Talairach space and intensity normalization (Sled
et al., 1998), skull-stripping (Segonne et al., 2004), and labeling pre-
deﬁned brain regions including DGM and deep WM using a probabil-
istic atlas (Fischl et al., 2002; Fischl et al., 2004). DGM volume change
over time can be analyzed through the longitudinal stream (Reuter
et al., 2012), which uses an unbiased within-subject template that is
created using inverse consistent registration (Reuter et al., 2010), im-
proving reliability of volume change measurements (Reuter et al.,
2012).
TOADS is another automated brain segmentation tool that includes
segmentation of DGM structures (Bazin and Pham, 2007; Shiee et al.,
2010). TOADS uses a topological atlas to constrain not only the to-
pology of each brain structure, but also the relations between the
structures. In addition, it uses a shape atlas and intensity based tissue
classiﬁcation.
As described above for cortical regions, the methods based on es-
timating voxelwise partial volume or probability such as SPM or
SIENAX, can be used together with anatomical atlases as in IBASPM to
extract GM volumes of subcortical regions.
2.3. Group-level analysis methods
Two types of group-level analysis methods are important in the
context of this work. Voxel-based morphometry (VBM) is an extension
of voxelwise segmentation-based techniques such as SIENAX or SPM, in
which GM segmentation maps are transformed into a common space.
Similarly, individual vertexwise cortical thickness maps can be trans-
formed into a common space, for example in FreeSurfer. One can then
investigate diﬀerences between groups and correlations with other
variables for each voxel or vertex in the common space separately
(followed by appropriate corrections for multiple testing). A major
strength of such methods is that they allow the study of anatomical
patterns of atrophy without any a priori selection of regions of interest.
Salient regions and anatomical patterns can, therefore, be detected
from the data itself. A limitation of such techniques is that in order to
detect an eﬀect, e.g. a common GM atrophy pattern in MS patients,
there has to be substantial overlap between the true GM atrophy pat-
terns of individual patients in the study. For example, if a patient group
has reduced mean global GM volume compared to controls but the
locations of GM atrophy in the brain vary, the voxel-based and ver-
texwise group-level analysis methods may not detect any signiﬁcant
atrophy patterns. This limitation should be considered when inter-
preting such group-level VBM or vertexwise studies.
3. Challenges of pathology, physiology and treatment eﬀects
3.1. Unclear pathological substrate
Despite the importance of GM atrophy in MS, the underlying pa-
thological substrate is not well known. The extent and severity of
neuronal loss is less severe in MS than in a ‘classical’ neurodegenerative
disease such as Alzheimer's disease (Dutta et al., 2011; Haider et al.,
2014; Peterson et al., 2001). Nevertheless, a recent post mortem MRI
and histopathology study found that regional cortical atrophy is pre-
dominantly explained by a combination of (mild) neuro-axonal loss and
neuronal shrinkage (Popescu et al., 2015). The cortical atrophy was not
related to myelin loss (Popescu et al., 2015), despite (subpial) cortical
demyelination being frequent and extensive in (progressive) MS (Geurts
et al., 2005; Kutzelnigg and Lassmann, 2005). Another study found that
neuronal and axonal density did not diﬀer between subjects with nor-
mally myelinated GM and those with subpial cortical lesions (Klaver
et al., 2015), suggesting that neurodegeneration in MS cerebral cortex is
largely independent of cortical demyelination. It has also been shown
that the observed cortical volume reduction of around 10% in MS pa-
tients is independent of the presence of cortical lesions (Pareto et al.,
2016; Wegner et al., 2006). Although the work by Popescu et al., 2015
is valuable as a direct local association study between MRI atrophy
measures and pathological characteristics, the number of patients is
small and the results have to be conﬁrmed independently. It is therefore
imperative that more data is obtained on the pathological substrate of
cortical and subcortical grey matter atrophy in MS.
3.2. Evolution of GM atrophy
It is not clear which brain regions are most likely to develop GM
atrophy in the early phase of MS, whether the atrophic process is
mainly primary or secondary, or to what extent its evolution diﬀers
between disease types (Bishop et al., 2017; Calabrese et al., 2007;
Fisher et al., 2008). In part this arises from methodological issues such
as unknown sensitivities of diﬀerent measurement methods to atrophy
in diﬀerent GM regions. The concurrent evolution of focal lesions and
other pathological changes, together with the varying and partly un-
known eﬀects of diﬀerent treatments on GM atrophy, further compli-
cate understanding the natural evolution of GM in MS.
In relapse-onset MS, GM atrophy has been observed already in the
earliest phases of the disease (Bergsland et al., 2012; Calabrese et al.,
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2007). Moreover, GM atrophy may diﬀer between disease types (Fisher
et al., 2008; Sicotte et al., 2008), as well as between patients with and
without evidence of disease activity (Nygaard et al., 2015). Some evi-
dence also exists of early and eloquent GM atrophy in speciﬁc regions:
for example, in primary progressive MS, the involvement of the cin-
gulate cortex was found to occur throughout the disease course
(Eshaghi et al., 2014). Also, signiﬁcant GM volume loss occurred in the
right precuneus in relapsing-remitting MS patients with progressive
disability (Hofstetter et al., 2014). Moreover, atrophy of speciﬁc DGM
structures, most notably the thalamus, also occurs in MS patients
(Bishop et al., 2017; Houtchens et al., 2007; Schoonheim et al., 2015;
Solomon et al., 2017). Atrophy of the thalamus appears to occur
especially early and prominently, to be worse in men, and to be asso-
ciated with cognitive decline (Schoonheim et al., 2015). However, it
remains unclear to what extent these observations could be biased by
the size and partially limited contrast with the neighboring WM of the
thalamus. In general, more work is needed to validate the dynamic
changes and anatomical patterns observed in previous studies. Speci-
ﬁcally, the sensitivity of current techniques to measure atrophy of dif-
ferent anatomical regions should be quantitatively evaluated.
Although studies have shown that the relation between GM pa-
thology and WM lesions is an important factor in MS, this relation re-
mains to be fully elucidated (Geurts et al., 2012). Global WM lesion
volumes are associated with both global GM atrophy (Charil et al.,
2007; Roosendaal et al., 2011; Steenwijk et al., 2014) and local GM
atrophy (Charil et al., 2007; Sailer et al., 2003). Furthermore, there are
similarities between the average anatomical distribution of GM atrophy
and the distributions of both existing WM lesions (Bodini et al., 2009;
Muhlau et al., 2013; Riccitelli et al., 2012) and new WM lesions
(Battaglini et al., 2009; Bendfeldt et al., 2010). The relation of local GM
atrophy to lesional and non-lesional damage in connected WM tracts
has only been partially explored (Bergsland et al., 2015; Louapre et al.,
2016; Steenwijk et al., 2015) and further studies are needed to clarify
this.
How GM atrophy is related to other pathological changes inside the
GM has been less investigated. Longitudinal studies, in larger groups
and other clinical disease sub-types, are needed to fully answer the
questions about temporal and causal relations between GM atrophy and
other MS pathology, both in natural evolution and on treatment.
3.3. Inﬂuence of physiological variability
Eﬀects of physiological variability could aﬀect measurement of GM
atrophy; brain volumes have been shown to be aﬀected by, among
other, food intake (Roberto et al., 2011), steroids, (excess) body fat
(Janowitz et al., 2015), alcohol abuse (Thayer et al., 2016), and tobacco
smoking (Sutherland et al., 2016). One study (Sampat et al., 2010)
showed that, when using whole-brain volume change measures in an
MS trial, physiological ﬂuctuations may increase required sample sizes
by a factor of 5 compared to sample sizes based on scan-rescan re-
producibility error only.
Diﬀerent physiological sources of variability also have been in-
vestigated separately. Brain volumes decrease systematically during the
day, and by correcting for these diurnal ﬂuctuations, required sample
sizes in a typical trial could be reduced by 2.6% (Nakamura et al.,
2015). Brain volumes also diﬀered signiﬁcantly between hydrated and
dehydrated states induced by 16 h of no ﬂuid intake (Duning et al.,
2005). Although such extreme situations seem unlikely in MS clinical
practice, the eﬀect of hydration status should be taken into account. In
all, clear guidelines towards diminishing the impact of physiological
variations are needed before GM atrophy measurements can be con-
sidered in clinical practice.
3.4. Evaluation of treatment response
The eﬀect of disease modifying therapies may be diﬀerent for WM
than GM atrophy measures (Filippi et al., 2014; Fisher et al., 2016;
Perez-Miralles et al., 2015). Moreover, currently available therapies
predominantly target processes involved in formation of new WM le-
sions rather than atrophy. Therefore, tissue-speciﬁc brain volume
monitoring could provide diﬀerential insights on treatment eﬀects and
response (De Stefano et al., 2014) and help in the development of new
treatments. WM volume changes after starting treatment are heavily
dependent on baseline inﬂammation (Vidal-Jordana et al., 2016; Vidal-
Jordana et al., 2013). Therefore, immediate decreases in WM volume
after therapy onset need to be interpreted with great caution. This in-
itial pseudo-atrophy eﬀect does not seem to occur for GM (Prinster
et al., 2006). In addition, GM volume changes have been shown to be
relatively insensitive to baseline inﬂammation (Fisher et al., 2016;
Vidal-Jordana et al., 2016; Vidal-Jordana et al., 2013). Whether a
whole-tissue or a region-speciﬁc approach should be preferred, remains
to be elucidated and would depend on the acquisition of an a-priori
knowledge of the pathological substrate as well as the potential eﬀects
of any given drug on the speciﬁc regions.
Another important aspect is the inﬂuence of pre-existing damage on
GM atrophy development. As indicated above (“Evolution of GM
atrophy”), there is currently in general insuﬃcient data on the relation
between lesions and other damage in the WM on the one hand, and
(subsequent) atrophy of the GM on the other. Also, speciﬁcally whether
or not GM atrophy resulting from pre-existing WM damage may be
halted by treatment remains to be investigated. Studies should be
performed to provide such data, because otherwise interpretation of
data obtained in patients on treatment may be incorrect. If the sec-
ondary atrophy due to pre-existing damage cannot be halted, a situa-
tion may arise in which in a treated patient new GM atrophy is ade-
quately suppressed by treatment, but GM atrophy still progresses
merely as a late result of pre-existing WM lesions. In such a case, in
clinical treatment trials, these eﬀects of pre-existing WM damage on
current GM atropy may lead to an underestimation of the eﬀectiveness
of the treatment under evaluation. Similarly, in a clinical setting, the
treating physician may incorrectly conclude that the treatment is not
eﬀective on GM atrophy in that patient. It is therefore of great im-
portance to obtain data to understand the relation between WM damage
and GM atrophy and allowing, ultimately, the disentanglement of new
GM atrophy from GM atrophy that results from pre-existing WM da-
mage.
4. Measurement challenges
4.1. Inﬂuence of WM lesions
Several papers (Battaglini et al., 2012; Chard et al., 2010; Gonzalez-
Villa et al., 2017; Nakamura and Fisher, 2009) have shown that WM
lesions that are hypointense on T1-weighted images can aﬀect the as-
sessment of GM volumes, as illustrated in Fig. 1. One paper noted an
artiﬁcial GM volume underestimation in the presence of lesions with an
intensity between GM and WM, also when lesions were correctly re-
classiﬁed as WM (Nakamura and Fisher, 2009). Another study, using
synthetic data, found that the extent and the direction of the GM esti-
mation error depended strongly on the lesion load, on the degree of
hypointensity, and on the partial volume model used in the segmen-
tation algorithm (Battaglini et al., 2012).
The presence of T1 hypointense lesions, especially along tissue in-
terfaces, severely aﬀects non-linear registration of images (Di Perri
et al., 2008; Sdika and Pelletier, 2009). In VBM-type experiments, these
local distortions in registrations led to an overestimation of GM loss in
the cortex and in the DGM structures (Ceccarelli et al., 2012).
The most commonly used solution to these WM lesion-induced
problems is the so-called ‘lesion-ﬁlling’ or lesion ‘inpainting’, which
replaces WM lesion voxels with intensities similar to normal WM, using
parametric or numerical approaches to reproduce global or local WM
intensity histograms (Battaglini et al., 2012; Chard et al., 2010;
H. Amiri et al. NeuroImage: Clinical 19 (2018) 466–475
469
Gelineau-Morel et al., 2012; Prados et al., 2014; Sdika and Pelletier,
2009). Lesion-ﬁlling signiﬁcantly reduces the error due to the presence
of lesions in evaluating cortical and DGM volumes (Prados et al., 2014).
Moreover, lesion-ﬁlling signiﬁcantly improves the accuracy of local
CTh estimation, thereby also improving the whole-brain average CTh
measurement (Magon et al., 2014). A limitation of the lesion-ﬁlling
approach is that it requires accurate high-resolution segmentation of
the lesions. Nonetheless, even with low-resolution lesion segmentations
it is possible to measure the whole-brain GM volume from lesion-ﬁlled
images with good accuracy, although analysis of smaller GM regions
may be hampered by the remaining lesion voxels (Popescu et al., 2014).
Because of the importance of this issue, integrated segmentation algo-
rithms by which not only WM, GM and CSF but also lesions can be
segmented could be beneﬁcial.
4.2. Inﬂuence of atrophy itself
Paradoxically, the presence of brain atrophy distorts measurement
of that same brain atrophy, by aﬀecting various steps in the analysis
pipelines used.
Many analysis pipelines involve the removal of non-brain tissue
when measuring atrophy; the commonly used BET software (part of
FSL) was found to require fairly extreme parameter settings to perform
accurately in images of MS patients compared to manual brain ex-
traction (Popescu et al., 2012). Besides BET, other methods have also
been proposed to achieve accurate non-brain tissue in atrophic patient
scans including multi-atlas skull stripping (Doshi et al., 2013), OptiBET
(Lutkenhoﬀ et al., 2014), BrainMAPS (Leung et al., 2011), BEAST
(Eskildsen et al., 2012), and STEPS (Cardoso et al., 2013).
The accuracy of image co-registration, another step used in almost
all methods, also can be aﬀected by the presence of brain atrophy
(Pereira et al., 2010), as illustrated in Fig. 2. Proposed approaches to
overcome this problem include multi-channel registration using frac-
tional anisotropy (FA) maps from diﬀusion tensor imaging (DTI)
alongside T1-weighted images (Ceritoglu et al., 2009; Roura et al.,
2015), and inclusion of a-priori knowledge of ventricular shapes in the
presence of atrophy (Djamanakova et al., 2013). These are expected to
improve GM atrophy quantiﬁcation by better matching of templates,
priors, atlases and regions of interest; these approaches should be
evaluated correctly for better use and understanding.
As a very speciﬁc example, it has been shown that atrophy of the
WM aﬀects cortical surface curvature in MS (Deppe et al., 2014), which
could lead to incorrect interpretations of GM atrophy metrics based on
cortical surface reconstruction, depending on the method used.
4.3. Inﬂuence of other pathology
Beyond WM lesions and brain atrophy, focal GM lesions are pro-
minent in MS (Geurts et al., 2005; Kutzelnigg et al., 2005). The pre-
sence of such GM lesions also could have a signiﬁcant eﬀect on GM
volume estimations, as some of them may still be visible in the se-
quences frequently used for atrophy measurement such as MPRAGE
(Bagnato et al., 2006; Nelson et al., 2014). There is also abundant
evidence of diﬀuse GM and WM changes from post mortem and in vivo
studies (Raz et al., 2010; Seewann et al., 2009; van Munster et al., 2015;
Vrenken et al., 2010). The eﬀect of these diﬀuse WM and GM ab-
normalities on quantiﬁcation of atrophy measures, to the best of our
knowledge, has not been investigated and could aﬀect these measure-
ments. First, it is interesting that even a small volume of WM lesions can
have a substantial eﬀect on GM partial volume estimates throughout
the brain for segmentation techniques in which intensity distributions
of diﬀerent tissue classes are modelled (with or without priors), such as
FSL-FAST (Popescu et al., 2014). Second, subtle age or disease related
changes of the WM-GM contrast at the white matter – cortical border
have been shown to inﬂuence cortical thickness measurement system-
atically in a way that can be corrected statistically, at least at group
level (see Fig. 3) (Westlye et al., 2009). There is also evidence that
diﬀuse GM pathological abnormalities are more widespread and pos-
sibly independent of atrophy (Khaleeli et al., 2007; Mallik et al., 2015).
How these subtle GM and WM abnormalities aﬀect segmentation and
registration algorithms of the atrophy measurement pipelines is un-
known and this warrants further research.
4.4. Technical variability
MRI-derived GM atrophy measurements can exhibit large variability
due to causes related only to the MR image acquisition and analysis;
these problems are not speciﬁc to MS but occur equally in other dis-
eases that cause GM atrophy.
Concerning image acquisition, usually (near)isotropic 3D T1-
weighted images with similar acquisition parameters are used to
quantify brain atrophy. Nevertheless, remaining minor diﬀerences can
systematically aﬀect GM atrophy measurements. As an example, Fig. 4
shows how signal intensity and image contrast can change noticeably
even when only a single sequence parameter (the inversion time) is
slightly altered (from 450 to 400ms). Similarly, diﬀerent scanners can
give diﬀerent volumes or volume changes and this has been reported –
this can occur even when using similar or even identical acquisition
parameters (Durand-Dubief et al., 2012). Large systematic diﬀerences
have been observed between scanners for CTh and GM volume mea-
surements (Biberacher et al., 2016). Also, it has been shown that even
with identical scanners and imaging protocols, systematic diﬀerences of
GM volumes can occur (Takao et al., 2011).
Focusing on image analysis reproducibility, using the ADNI1 data
(http://adni.loni.usc.edu/), which contains a within-session rescan, i.e.
Fig. 1. The eﬀect of WM lesions on the segmentation using FSL-FAST software.
Left column: The native (non-ﬁlled) T1-weighted image and its WM segmen-
tation. Right column: T1-weighted image after lesion-ﬁlling and its WM seg-
mentation. Arrows point to obvious WM lesions. Color bar indicates the WM
partial volume estimate.
Reproduced in modiﬁed form with permission from Popescu et al. (2014).
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without repositioning, the reproducibility error was non-negligible
compared to typical atrophy rates for a commonly used whole-brain
software, SIENA (Cover et al., 2011). Moreover, for both FSL-FIRST and
FreeSurfer the within-session reproducibility error for measuring 1-year
hippocampal volume change was of similar size as the typical atrophy
rates (Mulder et al., 2014). A recent study (Cover et al., 2016) found
that some image analysis methods exhibited better reproducibility of 1-
year hippocampal volume change than others, leading to improved
statistical power and smaller required sample sizes in treatment trials.
Reproducibility of caudate nucleus, putamen, amygdala, globus pal-
lidus, and thalamus atrophy rates were found to be about 1.5–3.5 times
higher then the mean measured volume change across 500 Alzheimer's
disease, mild cognitive impairment and healthy elderly subjects for
both FreeSurfer and FSL-FIRST (Meijerman et al., 2018). In a smaller
group in MS, 3 T imaging yielded slight improvements of subcortical
volume reproducibility compared to 1.5 T by using FSL-FIRST (Chu
et al., 2017).
With respect to diﬀerences between diﬀerent image analysis
methods, in a longitudinal study, robustness across sites was better for
registration-based techniques than for segmentation-based techniques
(Durand-Dubief et al., 2012), although the data suggests that the im-
proved robustness across sites may come at the cost of a somewhat
reduced sensitivity to the volume change between time points. The two
most widely used methods for GM-VBM (FSL-VBM and SPM-VBM) gave
substantially diﬀerent results when comparing RRMS patients to
healthy controls, which was especially noticeable when considering
separate brain regions based on an anatomical atlas (Battaglini et al.,
2009). For volume measures in individual MS patients, volumetric
agreement between diﬀerent analysis methods (FreeSurfer, SPM, and
FSL) was only moderate to good for most DGM structures and cortical
regions, and correlations with clinical and cognitive measures varied
with the analysis method used (Popescu et al., 2016). Lastly, FreeSurfer
GM volume and CTh measurements depend on operating system,
FreeSurfer version and workstation type (Gronenschild et al., 2012).
A benchmark dataset is needed to establish and test the robustness
of analysis methods in the context of repeated scans within or between
scanners. Data acquired in MS patients is of special interest, because
that would allow users to concurrently investigate the eﬀects of lesions
and other pathology occurring in MS on the GM atrophy measurement.
5. Conclusions
We reviewed the state of the art regarding the most urgent chal-
lenges in the measurement of GM atrophy in MS, and provided re-
commendations to overcome them (summarized in Box 1). Diﬃculties
associated with physiological variability or with technical variability
between scans and image analysis methods extend beyond MS. There-
fore, the broader brain research community would beneﬁt from
(a) (b) (c) 
Fig. 2. An example of image misregistration due to
atrophy and a possible method for its improvement
based on multi-channel mapping. Warped contours
of lateral ventricles and surrounding regions are
superimposed on T1-weighted image as color over-
lays. (a) The red outline indicates the contour of the
lateral ventricle warped to the target image space by
default parameters FNIRT. This registration com-
pared to the actual location of the lateral ventricle
(white dotted line) is poor. (b) Taking into account
the large deformations necessary to co-register
images in the presence of severe atrophy (method
proposed by Djamanakova et al. (2013)) slightly
improved the registration. (c) Using a dual-channel
approach incorporating a coarse ventricle segmen-
tation in the target image space improved the lateral
ventricle registration substantially.
Reproduced in modiﬁed form with permission from
Djamanakova et al. (2013).
Fig. 3. The eﬀect of grey/white contrast on
cortical thickness measurement using
FreeSurfer. Statistical p maps thresholded
at p < 10−2 superimposed on a template
brain's semi-inﬂated surface showing the
results from GLMs testing the diﬀerence
between Alzheimer's disease (AD) and con-
trols (Con). Warm colors denote areas with
signiﬁcantly thinner cortex in AD compared
to controls. Adjusting for grey/white tissue
contrast (bottom row) increases sensitivity
to the AD-control diﬀerences in cortical
thickness over large portions of the brain
compared to results obtained when not ad-
justing for this contrast (top row).
Adopted with permission from Westlye
et al. (2009).
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addressing these challenges adequately. Some disease-speciﬁc technical
challenges also exist: while solutions are available to minimize the in-
ﬂuence of WM lesions on brain atrophy, the inﬂuence of diﬀuse damage
and of GM lesions remains to be elucidated. Such improvements are
needed to allow evaluation of GM atrophy independent of other MS
pathology. This would be achieved when the evolution of GM in un-
treated and treated patients, as well as its relation to the other MS
pathology can be properly understood. This understanding and the
technical improvements are also prerequisites to the use of GM atrophy
measures in the clinical routine.
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